Semaglutide is supplied in 0.25–2.4 mg pen; 3, 7, 14 mg oral. The standard approach is weekly injection titrated monthly from 0.25 mg toward 1.7–2.4 mg
Strength and use
| Strength | Typical role |
|---|---|
| 0.25–2.4 mg pen; 3 | Starting or low-dose maintenance |
| 7 | Standard maintenance dose |
| 14 mg oral | Escalation dose where response is partial |
Titration path
- 1
Step 1: initiate
Begin at the lowest useful strength of 0.25–2.4 mg pen; 3.
- 2
Step 2: assess
Review after the onset window of appetite effects within days, weight plateau at 60–68 weeks.
- 3
Step 3: escalate
Move up one strength only if the response is partial and tolerance is good.
- 4
Step 4: maintain
Hold at the lowest effective dose for type 2 diabetes and chronic weight management and review periodically.
Key takeaways
- Standard dosing: weekly injection titrated monthly from 0.25 mg toward 1.7–2.4 mg
- Dosing interval: 7-day half-life, once-weekly dosing.
- Never double up after a missed dose: resume the normal schedule.
- Store 2–8 °C cold chain until first use to protect potency across the shelf life.
Missed doses and adherence
If a dose is missed and the next one is close, skip it. Doubling increases the risk of nausea without improving outcomes. Blister packaging and clear dispensing labels measurably improve adherence on prefilled pen / oral tablet lines.
Semaglutide at a glance
| Attribute | Detail |
|---|---|
| Drug class | GLP-1 receptor agonist |
| Common brand | Ozempic / Wegovy / Rybelsus |
| Licensed use | type 2 diabetes and chronic weight management |
| Available strengths | 0.25–2.4 mg pen; 3, 7, 14 mg oral |
| Dosage form | prefilled pen / oral tablet |
| Typical onset | appetite effects within days, weight plateau at 60–68 weeks |
| Duration / dosing interval | 7-day half-life, once-weekly dosing |
| Storage | 2–8 °C cold chain until first use |
